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ABSTRACT
Purpose: Despite ongoing debate about best practices for managing inci-
dentally detected ﬁndings in brain research studies using magnetic reso-
nance imaging (MRI), this issue has not been investigated from a health
economics viewpoint. We applied a decision-analytic approach to assess
the beneﬁt of various strategies for functional MRI (fMRI) studies using
intracranial aneurysms (IA) as a model.
Methods: A decision tree and Markov model were created to simulate the
impact on the lifetime costs and quality-adjusted life-years (QALY) of four
different strategies for review of scans for the presence of IA. To populate
the decision model, we used current evidence from the literature and
results from a survey of experts.
Results: Review of the anatomical scans by a nonspecialist is not cost-
effective in any of the subgroups of participants. Full clinical examination
of women with a positive family history before enrollment in a study is
cost-effective. Cost-effectiveness of reviewing scans obtained from women
without a family history and men with a positive family history of IA
depends on the willingness-to-pay (l) for a QALY: at l of $50,000/QALY,
review of scans by a specialist is cost-effective, whereas at l of $100,000/
QALY, a full clinical workup is the best option. Compared with not
reviewing any scans, a customized strategy for each subgroup of partici-
pants results in an incremental cost-effectiveness ratio of $12,503 for
l = $50,000/QALY and $32,767 for l = $100,000/QALY.
Conclusion: Tailored strategies based on the characteristics of research
participants and l for one QALY are needed to address the problem of
incidental ﬁndings in research fMRI studies.
Keywords: cardiovascular disease, cost-utility analysis, economic evalua-
tion, functional neuroimaging.
Introduction
Incidental ﬁndings in healthy subjects or in patients recruited for
research are deﬁned as observations of potential clinical signiﬁ-
cance discovered unexpectedly and unrelated to the purpose of
the study [1]. In brain research involving magnetic resonance
imaging (MRI) for which the problem of incidental ﬁndings has
had particular importance, 2% to 8% of anomalies that are
detected require clinical follow-up with mostly low, but occa-
sionally a high, degree of urgency [2,3]. The question as to how
these ﬁndings should be handled in the context of purely experi-
mental imaging research, however, has been a topic of ongoing
debate and remains unresolved [1,4]. Strategies vary widely
across laboratories and institutions [5,6], with options ranging
from inaction (i.e., images are not screened for anomalies) to full
clinical-grade imaging of all participants before their enrollment
in a study [4].
The value of any strategy for the management of incidental
ﬁndings hinges upon the trade-off between the beneﬁts that come
from the unexpected diagnosis and treatment of potentially
health-threatening abnormalities on the one hand, and the extra
costs and possible psychological effects caused by false-positive
ﬁndings and/or overestimation of the signiﬁcance of ﬁndings on
the other. Although such trade-offs have been debated extensively
in the literature, there has not been any rigorous, quantitative
analysis based on decision theory. As a health policy issue, these
considerations are pivotal because research and health-care
budgets are limited. The decision to spend resources on one
particular approach is often at the expense of other alternatives
[7].
In the present work, we investigated different strategies to
manage incidental ﬁndings in brain functional MRI (fMRI)
research based on methods of economic evaluation. The litera-
ture suggests that vascular anomalies are the most prevalent
types of incidental ﬁndings [8]. Among the various brain dis-
eases, each with a distinct natural history and diagnostic and
therapeutic pathway, intracranial (vascular) aneurysms (IA) are
one of the most devastating [9]. If left untreated, IAs may spon-
taneously rupture and cause subarachnoid hemorrhage (SAH),
which can be associated with high mortality and morbidity.
There are, however, effective and relatively safe interventions for
IAs. This makes IAs a relevant ﬁrst target to rigorously evaluate
the merit of different screening approaches to research fMRI
studies. The aim of the present analysis was therefore to use IA as
a model, along with current best evidence and expert opinion, to
maximize expected beneﬁt in relation to expected costs with
respect to incidental ﬁndings in the context of research fMRI
studies.
Materials and Methods
We investigated four strategies for handling IAs in brain imaging
research involving participants 18 years and older who self-
report good health: 1) research scans are not routinely reviewed,
and no diagnostic or therapeutic workup is performed on any
participant; 2) research scans are reviewed by a researcher, often
a graduate student or postdoctoral fellow with no formal clinical
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training in radiology (“nonspecialist”), and are referred to an
MR-trained radiologist (“specialist”) for evaluation if a brain
anomaly is detected; if the ﬁnding is conﬁrmed to be suspicious
by the specialist, the participant is referred for a full diagnostic
workup; 3) research scans are referred directly to an MR radi-
ologist for formal review, and subjects with suspicious ﬁndings
are sent for full diagnostic workup; and 4) prior to study enroll-
ment, all research participants undergo a full workup including
clinical-grade magnetic resonance angiography (MRA).
We simulated the costs and health outcomes of these strate-
gies separately in 12 subgroups of research participants deﬁned
by three factors: age group (18–40, 40–60, and >60 years), sex,
and family history of IA. Positive family history was deﬁned by at
least two ﬁrst-degree relatives with IA/SAH. These three factors
are both easy to elucidate, and predictive of the risk of harboring
IAs [9]. The outcomes of the model were the costs (measured in
USD for the year 2007) accrued to society and the overall quality
of life of research participants. Both costs and health outcomes
were estimated through the lifetime of research participants. The
perspective of our analysis was societal. Health outcomes were
expressed as quality-adjusted life-years (QALYs). We applied a
future discount rate of 3% to both cost and effectiveness
outcomes.
A Decision Model for Incidental Finding of IAs
A decision-analytic model was built to simulate the natural
history of IA, the performance of diagnostic modalities, and the
impact of treatment for a hypothetical cohort of research partici-
pants. A simpliﬁed illustration of the structure of the decision
model is presented in Figure 1. The analytic model consisted of a
decision tree representing alternative strategies for initial man-
agement and further workup of a ﬁnding on an fMRI scan, and
a Markov model that simulated the remaining life-years of a
hypothetical individual. Each cycle in the Markov model corre-
sponded to 1 year, and the model was run for the lifetime of the
simulated subjects. In all strategies, individuals with a conﬁrmed
IA were given appropriate therapy, which might be surgical treat-
ment (clipping), nonsurgical endovascular treatment (coiling), or
assigned to “watch and wait” period during which the subject
does not receive treatment but is followed on a regular basis
[10,11]. Treatment has its own risk of immediate mortality or
permanent morbidity.
The model further assumed that subjects with an aneurysm
that did not undergo a formal review of their scans, or those
whose scans were reviewed but incorrectly classiﬁed as negative,
will live without the knowledge of their condition. They might
develop SAH or die from other causes. Those who develop SAH
might die immediately or might receive surgical/endovascular
treatment, which in turn has its own risk of adverse events
resulting in mortality or morbidity. Those who survive SAH and
surgical/endovascular intervention might still suffer from perma-
nent disability.
Evidence Synthesis
The point estimates and probability distribution of parameters
used in the model are presented in Table 1. We used the pub-
lished literature to estimate the model parameters. If the litera-
ture did not provide evidence on a particular aspect of the
model, we sought expert opinion. The latter was the case for
estimating the accuracy of detecting IAs on the anatomical scans
obtained before the acquisition of functional data by an MR
radiologist or a non–clinically trained researcher. We used a
survey questionnaire (please see the online Supporting
Information at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i6_asp) to systematically investigate
expert opinion about sensitivity and speciﬁcity of detecting an IA
as a function of IA size and reviewer expertise. Responders were
asked to choose the option that was closest to their opinion on
a 10-category scale (with 10% increments). The survey was sent
to 33 MR radiologists, neuroradiologists, and neuroimagers
with known research and clinical MR expertise in North
America and Europe. We received 10 responses (response rate
30%).
Costs were modeled in USD ($) for the year 2007 (Table 1).
We assigned zero costs to the initial evaluation by the nonspe-
cialists and considered elicitation of age and sex, and family
history of aneurysm from participants as a routine part of the
prescan interview, thus accruing no additional costs. We used the
medical component of the consumer price index [12] to adjust
costs reported in the literature for years other than 2007. Annual
direct costs for the ﬁrst 2 years after SAH were estimated from
Taylor et al. [13]. To calculate annual costs for the third and
subsequent years, we ﬁrst ran the model to estimate the remain-
ing life expectancy of individuals after SAH within each age
group. The discounted value of lifetime costs (adjusted to year
2007 values) after the second year was considered equivalent to
the lump-sum cost of stroke at the start of the third post-SAH
year. This value, estimated from Taylor et al. [13], was then
amortized into installments of equal size over the estimated
remaining years, with a discount rate of 3%. SAHs that resulted
in death in the same admission were assumed to incur 65% of the
total direct costs of the ﬁrst year [14]. We assumed that the costs
of the complication of treatment for IA equal that of ischemic
stroke, and estimated the lifetime costs of IA treatment compli-
cation accordingly [13]. We followed the recommendation of the
US Panel on Cost-Effectiveness in Health and Medicine [15] and
excluded productivity costs from the reference case analysis.
Utilities were estimated from various sources from the litera-
ture and are presented in Table 1. We used US norm values of
EQ-5D, by age group and sex, as the baseline utility for the
normal population [16]. Because the literature is very limited
regarding the psychological impact of knowing about the pres-
ence of an IA, we used the results of a prospective Danish study
on aortic abdominal aneurysm treated conservatively (“watch
and wait”), which reported 5% to 7% lower quality of life scores
than in the general population (measured by screen QL, a generic
quality of life questionnaire) [17]. The quality of life of patients
improved after surgical treatment and was comparable to that of
the normal population. Based on these results, we assumed a
reduction in utility of 0.05 for individuals who are diagnosed
with IA but are being followed with a “watch and wait” conser-
vative approach. We assumed that the experience of having a
brain aneurysm or SAH in the past does not reduce the quality of
life after successful treatment without residual morbidity.
Analysis
We calculated the incremental cost-effectiveness ratio (ICER)
between successively more expensive strategies (strategy 2 vs. 1,
strategy 3 vs. 2, and strategy 4 vs. 3). However, if a strategy was
dominated (higher costs and lower QALYs) by the previous
strategy, it was removed from the subsequent ICER calculations.
In determining the cost-effective strategy for each subgroup of
individuals, a threshold value for QALY (willingness-to-pay, l)
has to be established [18]. The most common value for l used in
the contemporary literature is $50,000/QALY; however, there
has been recent evidence that society is actually paying a much
higher value for one QALY or life-years gained [19,20]. There-
fore, we conducted the analysis for both willingness-to-pay
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values of $50,000/QALY and $100,000/QALY. Because the
analysis was separately run for each of the 12 subgroups of
research participants, we were able to construct a customized
strategy by picking the optimal strategy within each subgroup.
The optimal strategy was determined to be the one with the
highest net monetary beneﬁt (NMB) [21]. We then calculated the
societal costs and QALYs associated with such customized strat-
egy by weighted-averaging the costs and QALYs of the strategy
with the highest NMB within each subgroup, with weights being
the relative proportion of each subgroup in the population of
typical fMRI research participants. That is, if the proportion of
subjects within each of the 12 subgroups is p1, p2, . . . , p12, and
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Death
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Figure 1 Schematic illustration of the decision tree (top, see text)* and Markov model simulating future life-years of hypothetical individuals with untreated
aneurysm in the model (bottom). *For simplicity, stratiﬁcation on baseline covariates and categorization of aneurysms by size are omitted from the illustration, and
the full diagnostic workup is represented as a single step. Rectangles are states at which subjects remain for at least 1 year. Ovals are snapshot events. SAH,
subarachnoid hemorrhage.
Screening for Brain Aneurysms in fMRI Studies 763
Table 1 Parameters of the model*
Parameter Mean value (95% CI) Distribution Reference
Prevalence of aneurysm
20–40 0.014 (0.008–0021) Beta [34]
40–60 0.018 (0.014–0.021) Beta
>60 0.022 (0.018–0.024) Beta
RR for aneurysm with a positive family history 4.0 (2.7–6.0) Log-normal [34]
RR for aneurysm for female (vs. male) 1.25 (0.9–2.0) Log-normal [34]
Proportion of aneurysms by size (mm)
Small (<6) 0.72 Dirichlet distribution assuming
estimates are based on a
sample of 100 observations
[34]
Medium (6–10) 0.21
Large (>10) 0.07
Sensitivity of the nonspecialist (by aneurysm size, mm) Multivariate logit-normal
distribution
Survey (see text)
Small (<6) 19.2% (6.3–39.6)
Medium (6–10) 34.1% (17.2–55.1)
Large (>10) 60.6% (31.9–82.6)
Speciﬁcity of the nontrained researcher 80.8% (93.7–60.4)
Sensitivity of the specialist (by aneurysm size, mm)
Small (<6) 33.4% (7.7–74.4)
Medium (6–10) 49.6% (24.0–80.1)
Large (>10) 77.5% (54.6–92.8)
Speciﬁcity of the specialist 88.7% (80.2–92.9)
OR for consistent reading of the same scan by
nonspecialist and specialist
2.0 (1.0–3.0) Uniform Assumption
Accuracy of clinical-grade imaging
Sn of CTA (small IA) 0.61 (0.52–0.70) Beta [35]
Sn of CTA (medium-sized IA) 0.94 (0.90–0.97)
Sn of CTA (large IA) 0.99 (0.97–1.0)
Sp of CTA 0.95 (0.89–0.98)
Sn of MRA (small IA) 0.47 (0.34–0.61)
Sn of MRA (medium-sized IA) 0.92 (0.88–0.96)
Sn of MRA (large IA) 0.99 (0.96–1.0)
Sp of MRA 0.92 (0.88–0.94)
Annual incidence of SAH in those with IA
Based on Wermer et al.
All aneurysms† 0.00887 (0.0067–0.01) Log-normal [29]
RR for medium vs. small 2.3 (1.0–5.2) Log-normal [29]
RR for large vs. small 7.5 (3.8–14.2) Log-normal [29]
Based on ISUIA (mm)
Small (<6) 0.00017 Fixed (used only in
deterministic sensitivity
analysis)
[36]
Medium (6–10) 0.01273
Large (>10) 0.02672
RR of SAH for female (vs. male) 1.6 (1.1–2.4) Log-normal [29]
Adverse events associated with treatment of aneurysm
Immediate mortality (clipping) 0.026 (0.02–0.033) Beta [37,38]
Immediate mortality (coiling) 0.004 (0–0.012) Beta
Long-term morbidity (clipping) 0.058 (0.051–0.065) Beta
Long-term morbidity (coiling) 0.028 (0.016–0.047) Beta
Adverse events associated with SAH
Immediate mortality 0.45 (0.32–0.67) Beta [39]
Long-term morbidity 0.15 (0.10–0.20) Beta [39]
Costs
CTA 774.3 (467.6–1157.0) Gamma [40]
MRA 627.0 (347.1–989.9) Gamma [27]
Preoperative angiography 1,569.2 (812.3–2571.2) Gamma [27]
Cost of treatment of unruptured aneurysm
Surgical 32,332 (21,739–44,996) Gamma [37]
Nonsurgical 26,560 (15,937–39,853) Gamma
Acute cost of SAH
Annual cost of morbidity due to SAH Direct costs year 1: 65,887 (40,239–97,731) Gamma [13]
Direct costs year 2: 8,977 (5,483–13,318)
Direct costs other years: 5,588 (3,413–8,290)
Annual indirect costs: 22,354 (13,654–33,163)
Annual cost of morbidity due to IA complications Direct costs year 1: 31,841 (19,449–47,237) Gamma [13]
Direct costs year 2: 11,021 (6,731–16,350)
Direct costs other years: 5,588 (3,413–8,290)
Annual indirect costs: 28,850 (17,622–42,801)
Utilities
Well without aneurysm Age Sex Mean Normal with standard
deviation of 0.01
US norm values for
EQ-5D [16]18–40 Male 0.89
Female 0.89
40–60 Male 0.88
Female 0.87
>60 Male 0.86
Female 0.84
Well with conﬁrmed aneurysm (duration: lifetime) Utility of “well without aneurysm” minus 0.05 (0.02–0.07) Beta [17]
Well after successful treatment of aneurysm/SAH
(duration: lifetime)
Same as “well without aneurysm” Fixed Assumption
Permanent morbid after treatment of aneurysm
(duration: lifetime)
0.7 (0.6–0.8) Beta [41]
Permanent morbidity due to SAH (duration: lifetimes)‡ 0.26 (0.11–0.39) Beta [42,43]
Immediate postsurgery (duration: 1 month) 0.6 (0.5–0.7) Beta [41]
*The parameters of the distributions were ﬁtted to match the mean and upper bound of the reported CI values.
†Fixed-effect pooling of three categories of follow-up.
‡Based on the moderate/severe disability after stroke.
CI, conﬁdence interval; IA, intracranial aneurysm; OR, odds ratio; RR, relative risk; SAH, subarachnoid hemorrhage; Sn, sensitivity; Sp, speciﬁcity.
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the cost is, respectively, c1, . . . , c12, then the cost of the cus-
tomized strategy is p1 ¥ c1 + p2 ¥ c2 + . . . + p12 ¥ c12. The
calculation of the QALY, number of IAs detected, and incidence
of SAH are also the same. To determine the weights p1 to p12,
we pooled the age and sex distribution from a convenience
sample of fMRI studies (studies published in English and indexed
in Medline during the last 3 months of 2008). Separate custom-
ized strategies were constructed for l-values of $50,000/QALY
and $100,000/QALY. We also calculated the ICER between the
two customized strategies compared with the strategy of no
screening (strategy 1).
The decision tree and Markov model were created and run
using the computer program TreeAge (Pro 2008 suite, TreeAge
Software Inc., Williamstown, MA). We used R (version 2.8.1) for
joint estimation of the accuracy of nonspecialists and specialists
in detecting IA (please see the online Supporting Information at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i6_asp for statistical analysis of the survey data).
Deterministic and Probabilistic Sensitivity Analysis
We studied the impact of uncertainty in the underlying evidence
on the results by conducting both deterministic and probabilistic
sensitivity analyses (PSA). In deterministic sensitivity analysis,
the values of parameters were changed one at a time to arbitrarily
deﬁned extremes, and calculations were repeated. In the deter-
ministic analysis, we also included alternative assumptions about
different discount rates (0% and 5%). There is a lack of consen-
sus in the literature on the inclusion or exclusion of productivity
costs in economic evaluations conducted from a societal perspec-
tive [22,23]. While in the reference case we followed the recom-
mendations of the US Panel on Cost-effectiveness in Health and
Medicine and excluded productivity costs, we repeated all analy-
ses with productivity costs included.
We conducted the PSA by assigning probability distributions
to uncertain parameters of the model, randomly drawing from
the distributions of all uncertain parameters (second-order simu-
lation), and calculating model outcomes; this cycle was repeated
1000 times. The choice of the probability distribution was based
on the scale of the parameter (e.g., beta distribution of probabili-
ties, gamma distribution for costs, log-normal distribution for
relative risks). Parameters of the distributions were chosen to
match the reported standard error or conﬁdence interval (CI) of
the parameter. For sensitivity and speciﬁcity of specialists and
nonspecialists reading fMRI scans, we picked random samples
directly from the posterior distribution of parameters from the
statistical analysis. PSA was conducted to calculate 95% CI for
outputs of the reference case analysis and to calculate the prob-
ability that each of the four individual strategies or the custom-
ized strategy would be cost-effective in the overall population
depending on society’s l (the cost-effectiveness acceptability
curve, or CEAC [24]). In constructing the CEAC, we allowed the
composition of the customized strategy to be determined sepa-
rately at each l-value.
Results
Table 2 presents the costs, QALYs, and ICERs associated with
the four strategies and the two customized strategies for l-values
of $50,000/QALY and $100,000/QALY. Compared with strategy
1, the customized strategy based on l = $50,000/QALY results in
a $90.4 (95% CI 41.4.8–169.2) increase in societal costs during
the lifetime of subjects and a gain in QALY of 0.0072 (95% CI
0.0025–0.0165). In other words, by adopting such a customized
strategy, society would pay $12,503 for obtaining one additional
QALY compared with the strategy of not screening research
subjects. Likewise, compared with strategy 1, the customized
strategy based on l = $100,000/QALY results in a $354.7 (95%
CI 211.8–520.7) increase in societal costs during the lifetime of
subjects and a gain in QALY of 0.0108 (95% CI 0.0078–
0.0246). In other words, by adopting such a customized strategy,
society pays $32,767 for obtaining one additional QALY com-
pared with the strategy of not screening.
Depending on different age groups, sex, family history of IA,
and decision-maker’s l, different strategies are cost-effective in
different subgroups. Findings can be summarized as follows:
• Review of scans for incidental ﬁndings by a nonspecialist
(strategy 2) is not cost-effective for any of subgroups.
• In men without a family history of IA, no review of scans is
cost-effective.
• Clinical-grade MR examinations including MRA (strategy
4) for women with a positive family history before enroll-
ment in a study are cost-effective.
• For women without a family history and men with a posi-
tive family history, the cost-effective strategy is different for
the two l-values: for l = $50,000/QALY, radiologist review
of scans (strategy 3) is cost-effective, whereas for
l = $100,000/QALY, a full clinical-level screening (strategy
4) is the cost-effective option.
Figure 2 illustrates the number of aneurysms detected after
initial review and the lifetime incidence of SAH per 1000 indi-
viduals. As expected, more aggressive review strategies yield
higher aneurysms detection rates and lower rate of future SAH
events. For both immediate IA detection and SAH incidence, the
customized strategy results in more favorable numbers than the
strategy of no review and review by nonclinically trained
researcher (strategies 1 and 2), but is less favorable than initial
review by specialist and a clinical-grade preenrollment MRI
(strategies 3 and 4). Compared with strategies 1 and 2, the
customized strategy based on l = $50,000/QALY averts one
Table 2 Reference case results
Strategy Cost (95% CI) QALY (95% CI) ICER
1 $225.9 (126.2–373.5) 26.5015 (25.9378–27.0301) Ref
2 $268.0 (151.3–461.9) 26.4972 (25.9332–27.0401) Dominated (vs. strategy 1)
3 $404.2 (259.2–608.2) 26.5068 (25.9450–27.0466) $33,864 (vs. strategy 1)
4 $1,004.0 (699.5–1,335.8) 26.5132 (25.9465–27.0514) $93,392 (vs. strategy 3)
Customized (l = $50,000/QALY) $316.3 (211.9–479.6) 26.5087 (25.9492–27.0421) $12,503 (vs. strategy 1)
Customized (l = $100,000/QALY) $580.6 (422.6–768.1) 26.5123 (25.9468–27.0536) $32,767 (vs. strategy 1)
Costs and QALYs associated with the four reviewing strategies and two customized strategies.
CI, conﬁdence interval; QALY, quality-adjusted life-years.
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SAH event per 1737 and 5103 participants, respectively, whereas
the customized strategy based on l = $100,000/QALY averts one
SAH per 1150 and 2026 participants.
Deterministic Sensitivity Analysis
When productivity is included in societal costs [13], the lifetime
costs of strategies 1 to 4 increases, respectively, to $408.4,
$434.8, $552.0, and $1130.4. The strategies with the highest
NMB remain the same, except for the subgroup of male subjects
40 to 60 years old with a positive family history. For this group,
strategy 4 is cost-effective at both l-values. When productivity
costs are included, the lifetime cost of the customized strategy is
$477.1 for l = $50,000/QALY and $725.7 for l = $100,000/
QALY. The corresponding ICERs associated with these two
l-values are $9429/QALY and $29,313/QALY, respectively.
We found that the prevalence of IA and the annual rupture
rate are the two parameters that have signiﬁcant impact on the
results. At l = $50,000/QALY, with either a 20% higher preva-
lence of IA or 20% higher rupture rate, more aggressive
approaches such as full clinical preenrollment screening is
cost-effective in female participants, whereas with a 20% lower
prevalence or rupture rate, the strategy of not reviewing is cost-
effective in male subjects. Results are relatively robust against
changes in other model parameters, except when a higher sensi-
tivity (10% higher than the reference case value) is assigned to
specialist review, for which strategy 3 becomes cost-effective for
male subjects older than 60 years at l = $50,000/QALY. More
detailed results of one-way sensitivity analysis are presented at
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i6_asp.
Probabilistic Sensitivity Analysis
Results of the PSA are presented in Figures 3 and 4. Figure 3
demonstrates the probability that each of the four strategies has
the highest NMB within each subgroup at l = $50,000/QALY (a
similar graph for l = $100,000/QALY is presented in the online
Supporting Information at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH13i6_asp). Overall, the uncertainty
in the underlying evidence results in considerable doubt in the
choice of the cost-effective strategy within each subgroup and
hence the composition of the customized strategy. Such uncer-
tainty differentially affects the conﬁdence in the choice of the
optimal strategy within each subgroup. For example, there is
little doubt that strategy 1 (no review) is the cost-effective option
Figure 2 The incidence of true-positive aneurysm
detections after initial review and lifetime incidence
of SAH corresponding to each strategy. Strategy 1:
no review; strategy 2: initial nonspecialist review
followed by MR radiologist review; strategy 3: MR
radiologist review; strategy 4: clinical-grade MR
examination including MRA. IA, intracranial aneu-
rysm; MR, magnetic resonance; MRA, magnetic
resonance angiography; SAH, subarachnoid hemor-
rhage;WTP, willingness-to-pay.
Figure 3 Proportion of times each of the four
review strategies was found to be the best option
in the stochastic sensitivity analysis. Strategy 1: no
review; strategy 2: initial nonspecialist review fol-
lowed by MR radiologist review; strategy 3: MR
radiologist review; strategy 4: clinical-grade MR
examination including MRA. MR, magnetic reso-
nance; MRA, magnetic resonance angiography.
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for men older than >60 years with a negative family history,
whereas strategies 3 and 4 have almost equal chances of being
cost-effective for men 40 to 60 years old with a positive family
history. However, even with this degree of uncertainty, the strat-
egy of initial review by a nontrained researcher is very unlikely to
be a good choice (less than 5% chance in any subgroup).
Figure 4 shows the CEAC for each of the four original strat-
egies and the customized strategy across a wide range of society’s
l for one QALY. For the entire range of l in this ﬁgure ($0–
200,000/QALY), the probability that the customized strategy is
cost-effective is greater than 60%. At the reference values of
$50,000/QALY and $100,000/QALY, the customized strategy
has 81% and 70% chance of being cost-effective, respectively.
Discussion
The appropriate and efﬁcient use of resources in research, as in
health care, is an ethical obligation [7]. Therefore, decisions
about how to manage ﬁndings detected incidentally in brain
imaging studies should be informed by costs that affect both
research and health-care budgets [5]. Our results indicate that
where the detection of IA in fMRI studies is concerned, there is
no single optimal strategy. Rather, from a health economics point
of view, an approach that is customized to subjects’ sex, age, and
family history is needed. We found that review of scans by a
researcher not formally trained in radiological interpretation is
not appropriate for any of the subgroups. This is mainly due to
the fact that the sequential review of scans by the researcher and
clinician in this strategy reduces the overall sensitivity (as both
should label the scan as positive). Although there is considerable
uncertainty as to which option is cost-effective for any particular
subgroup, there is little uncertainty that a customized strategy
based on the demographic variables of research participants is
cost-effective (as demonstrated by the high probability of cost-
effectiveness in Fig. 4), and that the strategy of initial review by
a nontrained researcher is not a good value for money.
We believe that our results have important public health
implications. Our recent review of the literature [25] revealed
that from 2002 to 2008, there were 1852 fMRI studies per year
involving human subjects on average, with an annual growth rate
of 5.8%. Assuming that an fMRI study involves a minimum of
10 subjects, and that results of our analysis will remain valid for
the next 10 years [26], implementation of the customized strat-
egy compared with the strategy of initial review by non–clinically
trained researcher—a strategy commonly used by research labo-
ratories [6]—will save 1889 QALYs in the next 10 years at the
value of $12,503 per QALY. This ﬁgure is considered cost-
effective based on the interventions in health care that are typi-
cally funded [19].
We decided to use two willingness-to-pay thresholds for
QALY to compare our results with similar economic evaluations
and with the implicit monetary value of a healthy life-year in
Western countries. For l-value of $50,000/QALY, a full clinical
workup, including a MRA, is cost-effective for prospective
female subjects of all age groups who have a positive family
history. Such a strategy also becomes cost-effective for men with
a positive family history and all women at l = $100,000/QALY.
Making ﬁnal decisions on the appropriate screening is the
responsibility of investigators, and given the prohibitive costs of
clinical examinations for research, an ethically acceptable alter-
native might be to exclude participants a priori for whom a
clinical-level screening is the optimal choice.
In modeling the strategy of review with a clinical-grade MRA,
we assumed the information in the fMRI anatomical scan is
negligible compared with that of MRA. Thus, the recommenda-
tion for an MRA scan for some subgroups implies that mass
screening for IAs using MRA would be cost-effective in these
subgroups at the population level. This view has been supported
recently by a cost-effectiveness analysis by Takao et al. [27]. They
found that in family members with two or more affected ﬁrst-
degree relatives, screening compared with no screening had an
ICER of $37,400/QALY (year 2003 USD, societal perspective).
They did not stratify their analysis on sex. However, by merging
the results for men and women, the corresponding ICER for our
analysis is $24,630/QALY. Given the complexity of modeling
and evidence synthesis, a number of factors might account for
this difference. A primary source of difference may be estimates
of rupture rates from the International Study of Unruptured
Intracranial Aneurysms study by Takao et al. [28] compared with
a meta-analysis in our study [29] that included ISUIA in addition
to other reports.
Our study has several limitations. Foremost is that the analy-
sis is restricted only to the review of scans for IA, which,
although in the category of vascular anomalies seen most fre-
Figure 4 Probability of the cost-effectiveness of
different strategies based society’s willingness-to-
pay for one QALY. Willingness-to-pay: society’s
willingness to pay to gain one quality-adjusted life-
year in an individual.The dashed lines correspond
to the willingness-to-pay value of $50,000/QALY
and $100,000/QALY. Strategy 1: no review; strategy
2: initial nonspecialist review followed by MR radi-
ologist review; strategy 3: MR radiologist review;
strategy 4: clinical-grade MR examination including
MRA. MR, magnetic resonance; MRA, magnetic
resonance angiography; QALY, quality-adjusted
life-years.
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quently [8], is one of many incidentally found brain lesions.
According to Vernooij et al. [8], if 1000 healthy volunteers were
reviewed with brain MRI, 18 would have aneurysms, 72 would
have infarcts, 16 would have benign tumors, 9 would have
meningiomas, and many others would have less frequent anoma-
lies. In this context, it is therefore reasonable to expect that the
person who reviews the anatomical scans for suspicious ﬁndings
will look for any abnormality and not just an aneurysm. As such,
a ﬁnding that may be a false positive with regard to an aneurysm
might in fact, with subsequent review by an MR radiologist or
with additional clinical imaging, lead to the diagnosis of another
condition that could also beneﬁt the research participant. This
will deﬁnitely alter the numerical values of ICERs reported here
and might cause other review strategies to emerge as the best
choice. Nevertheless, we believe our results are still valuable. For
example, the ﬁnding that the strategy of initial review of the
scans by non–clinically trained researcher is not an optimal
choice because of its low sensitivity is likely to remain valid when
other abnormalities are modeled. All in all, given the complexity
of incidental ﬁndings, a stepwise approach based one lesion type
at a time is most practical. Combinations of speciﬁc models could
be tested in the future to determine the economic value of a
general screening strategy for any type of incidental ﬁndings.
Although there have been newer studies on the cost of SAH
and stroke [30–32] than the one we used as reference for our
modeling, none provide lifetime direct and indirect costs of SAH
and stroke at the population level. A recent review of cost-of-
stroke studies reveals up to 20-fold variation in the estimated
costs of strokes even within the same country [14]. The authors
of this study reported a pooled value of $28,525 (year 2006
USD) for costs of stroke during the ﬁrst year, which is very close
to the value of $31, 841 (year 2007 USD) reported by Taylor
et al. [13] and used in our analysis.
We estimated demographic information and assigned weights
to each subgroup to calculate the outcomes of the customized
strategy from a convenience sample of fMRI studies. Distribution
of age, sex, and family history of IA might be variable across
different settings. Although the resulting difference in weights
will result in different ICER values for the customized strategy,
the composition of the customized strategy will not change by
using different weights, and ICER can always be recalculated
form the data provided in Table S1 in the online Supporting
Information (available at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH13i6_asp).
Because of the lack of information on the diagnostic perfor-
mance of non–clinically trained researchers and the diagnostic
information present in the anatomical but nonangiographic
MRI, we had to rely on expert opinion to estimate the relevant
components of the model. This method of evidence synthesis is in
line with the principle of the hierarchy of evidence [33] and
provides, within the limitation of our survey, the best available
evidence for our analysis. The performance characteristics of
specialists and non–clinically trained researchers might be a criti-
cal determinant of the beneﬁt of review, and more systematic
approaches to estimate these parameters could be a focus of
further research. Nevertheless, in our sensitivity analysis, increas-
ing or decreasing any single index of accuracy (by 10%) had
minimal effects on the ﬁnal results. We also acknowledge that the
expertise of the nontrained researcher will vary widely depending
on the researcher’s experience. The MR experts surveyed gave
substantially and consistently lower accuracy ratings to non-
trained researchers than to members of the professional groups
they represent. Although the statistical model used to pool the
results of the survey did allow for the non–clinically trained
researcher to have higher accuracy than the specialist, this was
the case in only 2% of the PSA samples, consistent with the
opinions of the respondents.
As our results show, individual characteristics of research
participants have an important bearing on the approach to inci-
dental ﬁndings. However, health economics arguments are not
the only ones that policymakers and principal investigators might
consider in the real world. A customized strategy is naturally
more difﬁcult to implement than a universally standardized one,
and imperfect adherence will result in reduced cost-effectiveness.
If investigators of fMRI studies decide to adopt a universal
strategy for research participants, then sending all scans for
specialist review (strategy 3) is the best option (see Table 2).
In conclusion, the results of the present decision analysis
provide a new source of information toward informed consensus
and best practices in the management of incidental ﬁndings in
fMRI research. We emphasize that many factors play important
roles in this interdisciplinary debate that are outside of the realm
of a purely decision-theoretic approach. Evidence-based policies
forthcoming from all domains—theoretical and empirical—must
be kept up to date with the continuously growing body of knowl-
edge about incidental ﬁndings.
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